Ceralasertib with durvalumab for treatment of previously treated non-small-cell lung cancer

Ceralasertib with durvalumab is in clinical development for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), for patients whose disease has progressed following immunotherapy (treatment that helps the body’s immune system fight diseases) and platinum chemotherapy (treatment using drugs containing platinum, which kills cancer cells by damaging their DNA). Metastatic NSCLC is lung cancer which has spread to other parts of the body such as the lungs, liver, and brain. Locally advanced NSCLC is lung cancer which has spread to tissues surrounding the lungs, but not distant sites in the body. Lung cancer symptoms can include persistent cough, chest infection that does not improve or repeated
chest infections, unexplained breathlessness, and coughing up blood. The most common cause of lung cancers is smoking, however other risk factors include air pollution, ageing, exposure to certain chemicals and lowered immunity. Advanced NSCLC can be difficult to treat due to the tumour cells becoming resistant to certain treatment mechanisms, meaning there are limited therapies available for patients with locally advanced or metastatic NSCLC.